SAB Biotherapeutics (SABS) Long-Term Deferred Tax (2020)

SAB Biotherapeutics' (SABS) quarterly Long-Term Deferred Tax came in at $235111.0 in Q4 2020.

SAB Biotherapeutics (SABS) Long-Term Deferred Tax (2020) Analysis & Trends

SAB Biotherapeutics (SABS) has 1 years of Long-Term Deferred Tax data on file, last reported at $235111.0 in Q4 2020.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $235111.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $235111.0 (changed N/A YoY) and the FY2020 annual result came in at $235111.0, changed N/A from the prior year.
Long-Term Deferred Tax was little changed at $235111.0 in Q4 2020.
In the past five years, Long-Term Deferred Tax ranged from a high of $235111.0 in Q4 2020 to a low of $235111.0 in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	SAB Biotherapeutics	308.92 Mn	308.92 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2020	235,111.00